Advertisement

Cutaneous Oncology in the Immunosuppressed

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Dermatologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Brin L.
        • Zubair A.S.
        • Brewer J.D.
        Optimal management of skin cancer in immunosuppressed patients.
        Am J Clin Dermatol. 2014; 15: 339-356
        • Brewer J.D.
        • Habermann T.M.
        • Shanafelt T.D.
        Lymphoma-associated skin cancer: incidence, natural history, and clinical management.
        Int J Dermatol. 2014; 53: 267-274
        • Mehrany K.
        • Byrd D.R.
        • Roenigk R.K.
        • et al.
        Lymphocytic infiltrates and subclinical epithelial tumor extension in patients with chronic leukemia and solid-organ transplantation.
        Dermatol Surg. 2003; 29: 129-134
        • Mehrany K.
        • Weenig R.H.
        • Pittelkow M.R.
        • et al.
        High recurrence rates of squamous cell carcinoma after Mohs' surgery in patients with chronic lymphocytic leukemia.
        Dermatol Surg. 2005; 31 ([discussion: 42]): 38-42
        • Velez N.F.
        • Karia P.S.
        • Vartanov A.R.
        • et al.
        Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia.
        JAMA Dermatol. 2014; 150: 280-287
        • Reusser N.M.
        • Downing C.
        • Guidry J.
        • et al.
        HPV Carcinomas in Immunocompromised Patients.
        J Clin Med. 2015; 4: 260-281
        • Asgari M.M.
        • Ray G.T.
        • Quesenberry Jr., C.P.
        • et al.
        Association of Multiple Primary Skin Cancers With Human Immunodeficiency Virus Infection, CD4 Count, and Viral Load.
        JAMA Dermatol. 2017; 153: 892-896
        • Deshmukh A.A.
        • Chhatwal J.
        • Chiao E.Y.
        • et al.
        Long-term outcomes of adding HPV vaccine to the anal intraepithelial neoplasia treatment regimen in hiv-positive men who have sex with men.
        Clin Infect Dis. 2015; 61: 1527-1535
        • Yarchoan R.
        • Uldrick T.S.
        HIV-associated cancers and related diseases.
        N Engl J Med. 2018; 378: 1029-1041
        • O'Reilly Zwald F.
        • Brown M.
        Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients.
        J Am Acad Dermatol. 2011; 65: 253-261
        • O'Reilly Zwald F.
        • Brown M.
        Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients.
        J Am Acad Dermatol. 2011; 65: 263-279
        • Euvrard S.
        • Kanitakis J.
        • Claudy A.
        Skin cancers after organ transplantation.
        N Engl J Med. 2003; 348: 1681-1691
        • Clarke C.A.
        • Robbins H.A.
        • Tatalovich Z.
        • et al.
        Risk of merkel cell carcinoma after solid organ transplantation.
        J Natl Cancer Inst. 2015; 107
        • National Comprehensive Cancer N
        Squamous cell skin cancer (Version 2.2021.
        (Available at:) (Accessed November 10, 2021)
        • National Comprehensive Cancer N
        Basal cell skin cancer (Version 2.2021.
        (Available at:) (Accessed November 10, 2021)
        • Crow L.D.
        • Jambusaria-Pahlajani A.
        • Chung C.L.
        • et al.
        Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines.
        Transpl Int. 2019; 32: 1268-1276
        • Kang W.
        • Sampaio M.S.
        • Huang E.
        • et al.
        Association of pretransplant skin cancer with posttransplant malignancy, graft failure and death in kidney transplant recipients.
        Transplantation. 2017; 101: 1303-1309
        • Al-Adra D.P.
        • Hammel L.
        • Roberts J.
        • et al.
        Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement.
        Am J Transplant. 2021; 21: 475-483
        • Massey P.R.
        • Schmults C.D.
        • Li S.J.
        • et al.
        Consensus-based recommendations on the prevention of squamous cell carcinoma in solid organ transplant recipients: a delphi consensus statement.
        JAMA Dermatol. 2021; 157: 1219-1226
        • Robbins H.A.
        • Clarke C.A.
        • Arron S.T.
        • et al.
        Melanoma risk and survival among organ transplant recipients.
        J Invest Dermatol. 2015; 135: 2657-2665
        • Brewer J.D.
        • Christenson L.J.
        • Weaver A.L.
        • et al.
        Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis.
        Arch Dermatol. 2011; 147: 790-796
        • Ulrich C.
        • Jurgensen J.S.
        • Degen A.
        • et al.
        Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study.
        Br J Dermatol. 2009; 161: 78-84
        • Acuna S.A.
        • Huang J.W.
        • Scott A.L.
        • et al.
        Cancer screening recommendations for solid organ transplant recipients: a systematic review of clinical practice guidelines.
        Am J Transpl. 2017; 17: 103-114
        • Jambusaria-Pahlajani A.
        • Crow L.D.
        • Lowenstein S.
        • et al.
        Predicting skin cancer in organ transplant recipients: development of the SUNTRAC screening tool using data from a multicenter cohort study.
        Transpl Int. 2019; 32: 1259-1267
        • Otley C.C.
        • Berg D.
        • Ulrich C.
        • et al.
        Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey.
        Br J Dermatol. 2006; 154: 395-400
        • Dantal J.
        • Morelon E.
        • Rostaing L.
        • et al.
        Sirolimus for secondary prevention of skin cancer in kidney transplant recipients: 5-year results.
        J Clin Oncol. 2018; 36: 2612-2620
        • Knoll G.A.
        • Kokolo M.B.
        • Mallick R.
        • et al.
        Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.
        BMJ. 2014; 349: g6679
        • Coghill A.E.
        • Johnson L.G.
        • Berg D.
        • et al.
        Immunosuppressive medications and squamous cell skin carcinoma: nested case-control study within the skin cancer after organ transplant (SCOT) cohort.
        Am J Transpl. 2016; 16: 565-573
        • Scott F.I.
        • Mamtani R.
        • Brensinger C.M.
        • et al.
        Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer.
        JAMA Dermatol. 2016; 152: 164-172
        • Karagas M.R.
        • Cushing Jr., G.L.
        • Greenberg E.R.
        • et al.
        Non-melanoma skin cancers and glucocorticoid therapy.
        Br J Cancer. 2001; 85: 683-686
        • Barbui T.
        • Ghirardi A.
        • Masciulli A.
        • et al.
        Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
        Leukemia. 2019; 33: 1996-2005
        • Johnson N.M.
        • Prickett K.A.
        • Phillips M.A.
        Systemic medications linked to an increased risk for skin malignancy.
        Cutis. 2019; 104: E32-E36
        • D'Arcy M.E.
        • Pfeiffer R.M.
        • Rivera D.R.
        • et al.
        Voriconazole and the risk of keratinocyte carcinomas among lung transplant recipients in the United States.
        JAMA Dermatol. 2020; 156: 772-779
        • Tee L.Y.
        • Sultana R.
        • Tam S.Y.C.
        • et al.
        Chemoprevention of keratinocyte carcinoma and actinic keratosis in solid-organ transplant recipients: Systematic review and meta-analyses.
        J Am Acad Dermatol. 2021; 84: 528-530
        • Mittal A.
        • Colegio O.R.
        Skin Cancers in Organ Transplant Recipients.
        Am J Transpl. 2017; 17: 2509-2530
        • Breithaupt A.D.
        • Beynet D.
        • Soriano T.
        Capecitabine for squamous cell carcinoma reduction in solid organ transplant recipients.
        JAAD Case Rep. 2015; 1: S16-S18
        • Totonchy M.
        • Leffell D.
        Emerging concepts and recent advances in basal cell carcinoma.
        F1000Res. 2017; 6: 2085
        • Ruiz E.S.
        • Karia P.S.
        • Besaw R.
        • et al.
        Performance of the american joint committee on cancer staging manual, 8th edition vs the brigham and women's hospital tumor classification system for cutaneous squamous cell carcinoma.
        JAMA Dermatol. 2019; 155: 819-825
        • Amin M.B.
        • Greene F.L.
        • Edge S.B.
        • et al.
        The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.
        CA Cancer J Clin. 2017; 67: 93-99
        • Jambusaria-Pahlajani A.
        • Kanetsky P.A.
        • Karia P.S.
        • et al.
        Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system.
        JAMA Dermatol. 2013; 149: 402-410
        • Sobin L.H.
        • Gospodarowicz M.K.
        • Wittekind C.
        TNM classification of malignant tumours.
        John Wiley & Sons, Oxford, UK2011
        • Morgan F.C.
        • Ruiz E.S.
        • Karia P.S.
        • et al.
        Brigham and Women's Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death.
        J Am Acad Dermatol. 2021; 85: 582-587
        • American Academy of D
        • American College of Mohs S
        • American Society for Dermatologic Surgery A
        • et al.
        AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery.
        Dermatol Surg. 2012; 38: 1582-1603
        • van Winden M.E.C.
        • Hetterschijt C.R.M.
        • Bronkhorst E.M.
        • et al.
        Evaluation of watchful waiting and tumor behavior in patients with basal cell carcinoma: an observational cohort study of 280 basal cell carcinomas in 89 patients.
        JAMA Dermatol. 2021; 157: 1174-1181
        • Rosenberg A.R.
        • Tabacchi M.
        • Ngo K.H.
        • et al.
        Skin cancer precursor immunotherapy for squamous cell carcinoma prevention.
        JCI Insight. 2019; 4: e125476
        • McLaughlin E.J.
        • Miller L.
        • Shin T.M.
        • et al.
        Rate of regional nodal metastases of cutaneous squamous cell carcinoma in the immunosuppressed patient.
        Am J Otolaryngol. 2017; 38: 325-328
        • Ruiz E.S.
        • Karia P.S.
        • Morgan F.C.
        • et al.
        The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management.
        J Am Acad Dermatol. 2017; 76: 217-225
        • Claveau J.
        • Archambault J.
        • Ernst D.S.
        • et al.
        Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma.
        Curr Oncol. 2020; 27: e399-e407
        • Krausz A.E.
        • Ji-Xu A.
        • Smile T.
        • et al.
        A Systematic review of primary, adjuvant, and salvage radiation therapy for cutaneous squamous cell carcinoma.
        Dermatol Surg. 2021; 47: 587-592
        • Manyam B.V.
        • Garsa A.A.
        • Chin R.I.
        • et al.
        A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck.
        Cancer. 2017; 123: 2054-2060
        • Hughes B.G.M.
        • Munoz-Couselo E.
        • Mortier L.
        • et al.
        Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.
        Ann Oncol. 2021; 32: 1276-1285
        • Migden M.R.
        • Rischin D.
        • Schmults C.D.
        • et al.
        PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma.
        N Engl J Med. 2018; 379: 341-351
        • Maubec E.
        • Petrow P.
        • Scheer-Senyarich I.
        • et al.
        Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
        J Clin Oncol. 2011; 29: 3419-3426
        • Leard L.E.
        • Cho B.K.
        • Jones K.D.
        • et al.
        Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab.
        J Heart Lung Transpl. 2007; 26: 1340-1344
        • Stratigos A.J.
        • Sekulic A.
        • Peris K.
        • et al.
        Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
        Lancet Oncol. 2021; 22: 848-857
        • Keeping S.
        • Xu Y.
        • Chen C.I.
        • et al.
        Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
        Future Oncol. 2021; 17: 611-627
        • Porceddu S.V.
        • Bressel M.
        • Poulsen M.G.
        • et al.
        Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial.
        J Clin Oncol. 2018; 36: 1275-1283
        • d'Izarny-Gargas T.
        • Durrbach A.
        • Zaidan M.
        Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review.
        Am J Transpl. 2020; 20: 2457-2465
        • Cook M.R.
        • Kim C.
        Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review.
        JAMA Oncol. 2019; 5: 1049-1054
        • Leiter U.
        • Loquai C.
        • Reinhardt L.
        • et al.
        Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
        J Immunother Cancer. 2020; 8
        • Fisher J.
        • Zeitouni N.
        • Fan W.
        • et al.
        Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review.
        J Am Acad Dermatol. 2020; 82: 1490-1500
        • Cusack C.A.
        • Nijhawan R.
        • Miller B.
        • et al.
        Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient.
        JAMA Dermatol. 2015; 151: 70-72
        • Rzepecki A.K.
        • Hwang C.D.
        • Etzkorn J.R.
        • et al.
        The rule of 10s versus the rule of 2s: High complication rates after conventional excision with postoperative margin assessment of specialty site versus trunk and proximal extremity melanomas.
        J Am Acad Dermatol. 2021; 85: 442-452
        • Flaherty K.T.
        • Infante J.R.
        • Daud A.
        • et al.
        Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
        N Engl J Med. 2012; 367: 1694-1703
        • Ressler J.
        • Silmbrod R.
        • Stepan A.
        • et al.
        Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report.
        Br J Dermatol. 2019; 181: 186-189
        • Tripathi S.V.
        • Morris C.R.
        • Alhamad T.
        • et al.
        Metastatic melanoma after solid organ transplantation: An interdisciplinary, institution-based review of management with systemic and targeted therapies.
        J Am Acad Dermatol. 2018; 78: 184-185
        • Paulson K.G.
        • Iyer J.G.
        • Blom A.
        • et al.
        Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage.
        J Invest Dermatol. 2013; 133: 642-646
        • Engels E.A.
        • Frisch M.
        • Goedert J.J.
        • et al.
        Merkel cell carcinoma and HIV infection.
        Lancet. 2002; 359: 497-498
        • National Comprehensive Cancer N
        Merkel Cell Carcinoma (Version 2.2021.
        (Available at:) (Accessed November 10, 2021)
        • Paulson K.G.
        • Lewis C.W.
        • Redman M.W.
        • et al.
        Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study.
        Cancer. 2017; 123: 1464-1474
        • Nghiem P.
        • Bhatia S.
        • Lipson E.J.
        • et al.
        Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
        J Clin Oncol. 2019; 37: 693-702
        • Cesarman E.
        • Damania B.
        • Krown S.E.
        • et al.
        Kaposi sarcoma.
        Nat Rev Dis Primers. 2019; 5: 9
        • Frances C.
        • Mouquet C.
        • Marcelin A.G.
        • et al.
        Outcome of kidney transplant recipients with previous human herpesvirus-8 infection.
        Transplantation. 2000; 69: 1776-1779
        • Regamey N.
        • Tamm M.
        • Wernli M.
        • et al.
        Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients.
        N Engl J Med. 1998; 339: 1358-1363
        • Stallone G.
        • Schena A.
        • Infante B.
        • et al.
        Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
        N Engl J Med. 2005; 352: 1317-1323
        • Donia A.F.
        • Fouda M.A.
        • Ghoneim M.E.
        • et al.
        The previously common post-kidney transplant Kaposi sarcoma has become non-existent for a decade: an Egyptian experience.
        J Cancer Res Clin Oncol. 2021; 147: 1493-1498